대한신장학회

논문분류	춘계학술대회 초록집
제목	Clinical significance of plasma matrix metalloproteinase-2 and matrix metalloproteinase-9 levels to assess the cardiovascular risk in hemodialysis patients
저자	Yu Ho Lee, Tae Young Yang, Hye yun Jeong, So-Young Lee, Yang Gyun Kim, Shin Young Ahn, Dong-Young Lee, Hyeon Seok Hwang
출판정보	2021; 2021(1):
키워드
초록	Objective: We prospectively enrolled 435 patients undergoing maintenance hemodialysis from K-cohort between June 2016 and April 2019. Plasma MMP-2, MMP-9 levels, and several biomarkers were measured at the time of study data entry. Primary endpoint was defined as a composite of cardiovascular events. Methods: Plasma MMP-2 level were increased in patients with incident CV events than those without CV events, whereas plasma MMP-9 levels were not different between groups. MMP-2 levels were positively correlated with circulating cardiac markers including brain natriuretic peptides (BNP), N-terminal proBNP, and heart-type fatty acid binding protein. The cumulative event rate of the composite of CV events was significantly greater in patients with higher MMP-2 tertile 3 than in those with other MMP-2 tertile 1 (p = 0.015). MMP-2 tertile 3 was associated with a 2.77-fold higher risk of the composite of CV events (95% CI, 1.40–5.45) and 4.67-fold higher risk of cardiac events (95% CI, 2.06–10.56) after multivariable adjustments. However, plasma MMP-9 levels were not positively correlated with circulating cardiac markers, and not associated with risk of incident CV events. Results: Higher plasma MMP-2 levels, but not MMP-9 levels, had the positive relationship with circulating levels of cardiac pathology markers, and were associated with increased risks of incident CV events and cardiac events among hemodialysis patients Conclusions: Objective: Matrix metalloproteinases (MMPs) are endopeptidases that control extracellular matrix synthesis and degradation. Two MMP subtypes, MMP-2 and MMP-9, are known to play important roles in the development and progression of cardiovascular (CV) disease, but its clinical relevance as predictors of cardiovascular events is unclear in hemodialysis patients. Methods: We prospectively enrolled 435 patients undergoing maintenance hemodialysis from K-cohort between June 2016 and April 2019. Plasma MMP-2, MMP-9 levels, and several biomarkers were measured at the time of study data entry. Primary endpoint was defined as a composite of cardiovascular events. Results: Plasma MMP-2 level were increased in patients with incident CV events than those without CV events, whereas plasma MMP-9 levels were not different between groups. MMP-2 levels were positively correlated with circulating cardiac markers including brain natriuretic peptides (BNP), N-terminal proBNP, and heart-type fatty acid binding protein. The cumulative event rate of the composite of CV events was significantly greater in patients with higher MMP-2 tertile 3 than in those with other MMP-2 tertile 1 (p = 0.015). MMP-2 tertile 3 was associated with a 2.77-fold higher risk of the composite of CV events (95% CI, 1.40–5.45) and 4.67-fold higher risk of cardiac events (95% CI, 2.06–10.56) after multivariable adjustments. However, plasma MMP-9 levels were not positively correlated with circulating cardiac markers, and not associated with risk of incident CV events. Conclusions: Higher plasma MMP-2 levels, but not MMP-9 levels, had the positive relationship with circulating levels of cardiac pathology markers, and were associated with increased risks of incident CV events and cardiac events among hemodialysis patients
원문(PDF)	PDF 원문보기

간행물 검색

대한신장학회 회원관리 규정